27 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
27966948	86	Discovery of Novel, Highly Potent, and Selective Matrix Metalloproteinase (MMP)-13 Inhibitors with a 1,2,4-Triazol-3-yl Moiety as a Zinc Binding Group Using a Structure-Based Design Approach.	Pharmaceutical
27825552	152	Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.	Takeda Pharmaceutical
26653735	81	Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.	Pfizer
26753813	22	Design and synthesis of an activity-based protein profiling probe derived from cinnamic hydroxamic acid.	University of Minnesota
25264600	64	Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.	Takeda Pharmaceutical
25686153	73	Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead.	University of Navarra
25192810	66	Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1¿ binding site.	Takeda Pharmaceutical
19715320	87	Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.	University of Florida
18061445	103	Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).	Bristol-Myers Squibb Research and Development
22175825	19	Potent inhibitors of LpxC for the treatment of Gram-negative infections.	Pfizer
22017539	75	Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13.	Boehringer Ingelheim Pharmaceuticals
18790648	317	Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.	University of Athens
18442906	40	Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.	North Dakota State University
17276676	112	A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
16473009	23	Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
11585440	76	Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.	Dupont Pharmaceuticals
30688452	94	Synthesis and Structural/Functional Characterization of Selective M14 Metallocarboxypeptidase Inhibitors Based on Phosphinic Pseudopeptide Scaffold: Implications on the Design of Specific Optical Probes.	Universitat Aut£Noma De Barcelona
7932530	2	Heteroaryl-fused 2-phenylisothiazolone inhibitors of cartilage breakdown.	Dupont Pharmaceuticals
29795754	72	Phenotypic Screening To Discover Novel Chemical Series as Efficient Antihemorrhagic Agents.	Universidad De Navarra
27996256	4	Zinc-Metalloproteinase Inhibitors: Evaluation of the Complex Role Played by the Zinc-Binding Group on Potency and Selectivity.	Universit£
28953404	70	Targeted Polypharmacology: Discovery of a Highly Potent Non-Hydroxamate Dual Matrix Metalloproteinase (MMP)-10/-13 Inhibitor.	Zhaw Zurich University of Applied Sciences
21524149	13	Design, synthesis and pharmacological evaluation of conformationally restricted N-arylsulfonyl-3-aminoalkoxy indoles as a potential 5-HT6 receptor ligands.	Suven Life Sciences
8632342	110	Pharmacologic characterization of the human 5-hydroxytryptamine2B receptor: evidence for species differences.	Eli Lilly
7651361	32	Characterization of (+/-)(-)[3H]epibatidine binding to nicotinic cholinergic receptors in rat and human brain.	Georgetown University